Skip to main content

Advertisement

Table 6 Summary of resource usage assumptions

From: Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist

Resource item Mean Sensitivity analyses Rationale
Lower Upper Distribution
Acute treatment
Number of days of acute treatment (i.e. LMWH) required by a DVT patient 9.6 6 10 Dirichlet EINSTEIN DVT [25]
SIGN guidelines [15]
Number of days of acute treatment (i.e. LMWH) required by a PE patient 9.7 7 13 Dirichlet Mean duration from EINSTEIN PE [26]
Proportion of patients who self-inject LMWH (%) 92 64.40 100 Beta The point estimate is taken from the assumptions in NICE CG92 [56]. The sensitivity range is an assumption
Proportion of remaining patients who require nurse assistance at home (%) 80 60 100% Beta These values are assumptions based on inputs determined for the NICE CG92 model
INR monitoring while on LMWH/VKA
Visits in first 3 months 9 5 15 Gamma EINSTEIN DVT [25,51]
SIGN guidelines [15,51]
Visits each 3 months thereafter 5 2.5 10 Gamma BNF [18,51]
Recurrent VTE: proportion treated as outpatients rather than inpatients
Recurrent DVT patients (%) 69 50 100 Beta SIGN guidelines [15]
Incident PE patients (%) 17 0 30 Beta Survey data
Other
Proportion of patients requiring NHS-funded transportation (%) 8.55 6 11 Beta Survey data
Proportion of CTEPH patients who require PEA (%) 68.40 64.20 72.60 Beta 321 of 469 patients from Condliffe 2008 [43]
Length of admission post DVT, days      van Bellen 2014 [52]
LMWH/VKA 8* 4 10   
Rivaroxaban 5* 3 9   
Length of admission post PE, days      van Bellen 2014 [52]
LMWH/VKA 7* 5 10   
Rivaroxaban 6* 4 9   
  1. *Median values.
  2. BNF, British National Formulary; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; INR, international normalized ratio; LMWH, low molecular weight heparin; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PE, pulmonary embolism; PEA, pulmonary endarterectomy; SIGN, Scottish Intercollegiate Guidelines Network; VKA, vitamin K antagonist; VTE, venous thromboembolism.